Investor Relations (2)

Hemostemix Boots on the Ground in Florida - October Update

Read More

Investor Relations, Latest News, Angina

Hemostemix Adds the treatment of Refractory Angina to its Phase 1 Basket Protocol

Read More

Hemostemix’s Insider Lead Order of $330,000 Private Placement

Read More

Hemostemix to Present its Clinical Data of the Treatment of Severe Angina

Read More

Hemostemix to Present at Life Science Investor Forum

Read More

Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share

Read More

Hemostemix Announces Private Placement

Read More

Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company

Read More

Hemostemix’ “Your Fountain of Youth” Trademark Granted by Japan Patent Office

Read More

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Read More